Exploratory Study of MRI Biomarkers of NASH
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Angers
About this trial
Metabolic steatosis disease (NAFLD) is a rapidly growing disease in the world, particularly in industrialized countries.
NAFLD is defined by the presence of fatty liver disease. This is a reversible phenomenon that can be estimated by non-invasive means, such as ultrasound. Non-invasive quantification, on the other hand, requires MRI.
Nonalcoholic steatohepatitis (NASH) is the aggressive form of the disease that promotes the accumulation of fibrosis in the liver, which can progress to cirrhosis and its complications.
Currently there is no non-invasive biomarker of NASH and the diagnosis is based solely on liver biopsy.
There is therefore a need for non-invasive biomarkers of NASH in patients with steatosis to diagnose NASH without the use of liver biopsy.
Eligibility criteria
Qualifiers
Patient included in the SNIFF cohort of the Angers hospital where there is a suspicion of NASH requiring a biopsy for which an MRI is requested by a hepatologist as part of the initial assessment of the disease.
Adult patient
Free, informed and express (oral) consent of the patient to participate in the study
Disqualifiers
Contraindication to MRI
Time between the establishment of the Steatosis/NASH status and the MRI greater than 3 months
Pregnant, parturient and breastfeeding woman
Person deprived of liberty by judicial or administrative decision
Trial design
Treatments tested in this trial
- Quantitative MRI sequences
Treatment groups
110 Participants
are divided into 1 treatment groupSponsors and collaborators
University Hospital, Angers
Lead sponsor
Angers University
Collaborator
Source ClinicalTrials.gov